Full-Time

Strategic Account Executive

Distribution & Channel Partners

Deadline 8/1/26
Omnicell

Omnicell

1,001-5,000 employees

Medication management and pharmacy automation platform

No salary listed

Fort Worth, TX, USA

Remote

Willing to travel 25-50% as needed.

Category
Sales & Account Management (1)
Required Skills
Sales
Public Speaking

Get referred to Omnicell

See people who can refer or advise you

Requirements
  • Bachelor’s Degree and 4 years of account management/relevant sales experience OR High School Diploma and 6 years of account management/ relevant sales experience.
  • Strong negotiation and contract management capabilities.
  • Proven ability to influence C-suite and senior executive decision-makers.
  • Strong presentation and public speaking skills, with experience presenting to both internal stakeholders and external customers.
  • Willingness and ability to travel 25-50% as needed.
Responsibilities
  • Demonstrate an understanding of industry drivers and trends that impact our customers and drive their business.
  • Manage and grow key distributor and reseller accounts, serving as the primary point of contact for large distribution partners operating across the US, Canada, and APAC. In this capacity, you will maintain full ownership of the account lifecycle – spanning initial onboarding and contract negotiations, through to quarterly business reviews, ongoing contract management, and long-term strategic growth planning.
  • Drive GPO partnership engagement, working to maximize the utilization and visibility of our portfolio within GPO channels, identifying opportunities to expand our presence and strengthen program performance.
  • Build and sustain relationships with key industry channel partners and organizations, ensuring Omnicell Medication Adherence is properly represented and positioned within the respective areas of focus.
  • Identify and pursue strategic growth opportunities by staying attuned to market trends, partner needs, and competitive dynamics across your territory. You will collaborate cross-functionally within internal teams – including product, marketing, and operations – to align resources and deliver on account objectives.
Desired Qualifications
  • Experience managing complex, high-value accounts across a national customer base.
  • Understanding of relevant Omnicell products/services/solution offerings for Long Term Care (LTC) or institutional pharmacy.
  • Strong negotiation, conflict management, and customer service experience; experience acting as the issue resolution liaison for the customer.
  • Experience working with wholesaler, distributor or reseller accounts.

Omnicell provides medication management solutions and adherence tools for health systems and pharmacies, combining pharmacy automation devices with cloud-based software to automate dispensing, manage inventory, and support patient adherence. The products mix hardware and a cloud platform that coordinates dispensing, inventory control, and clinical data through dashboards and analytics. Compared with competitors, Omnicell emphasizes a cloud-first software approach with a clear path to software-as-a-service and a hybrid direct-plus-partner sales model for end-to-end pharmacy automation and data services. Its goal is to realize the Autonomous Pharmacy by using automation and intelligent services to improve pharmacy care and patient outcomes while building recurring revenue.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Mountain View, California

Founded

1992

Get referred to Omnicell

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Titan XT targets a $2.5 billion installed-base replacement opportunity.
  • Recurring revenue is rising, with 2026 annual recurring revenue guided to $680–700 million.
  • Mandoli's May 2026 hire strengthens specialty pharmacy and 340B expansion execution.

What critics are saying

  • BD and other rivals can win hospital automation budgets through bundled contracts.
  • Hospital capital freezes delay Titan XT shipments and software conversion timing.
  • Tariffs add about $12 million of 2026 costs, pressuring hardware margins.

What makes Omnicell unique

  • Omnicell combines medication automation, software, and services across hospitals and pharmacies.
  • OmniSphere centralizes cloud-native pharmacy workflows and real-time inventory visibility.
  • Specialty Pharmacy Services and 340B expand Omnicell beyond cabinet hardware.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 5th, 2026
Omnicell's Titan XT cabinet launch divides analysts on $1.3B revenue outlook

Omnicell's analyst narrative centres on its Titan XT cabinet system and a potential hospital replacement cycle, though opinions diverge sharply on timing. The modelled fair value holds at $57.43 amid mixed price target revisions. BofA, Benchmark and KeyBanc have taken bullish stances, with KeyBanc upgrading to Overweight at $60, citing competitive wins and a cabinet refresh cycle. Conversely, Piper Sandler cut its target by $14, flagging execution and timing risks around the same Titan XT story. Omnicell issued Q1 2026 revenue guidance of $300 million to $310 million and full-year guidance of $1.215 billion to $1.255 billion. The company has launched Titan XT in the US, with international rollout expected later in 2026.

Yahoo Finance
Feb 28th, 2026
Omnicell targets $2.4B revenue by 2031 with shift to AI-driven pharmacy automation

Omnicell, Inc. is transitioning from hardware-driven revenue to a software and services model, aiming to double revenue from $1.18 billion to $2.4 billion by 2031, according to a bullish thesis on Danny's Substack. The company is expanding through strategic acquisitions like ANiGENT and developing its "Autonomous Pharmacy" vision using AI and robotics. The healthcare automation firm benefits from high switching costs, over 900 patents and a large installed base. Recurring revenue is approaching 50% of total revenue, with margins expected to expand from low teens to mid-20s. Bulls believe the market currently undervalues Omnicell as a hardware vendor, creating potential for significant rerating as it shifts towards healthcare IT, with shares trading at $38.61 as of 18 February.

Yahoo Finance
Feb 2nd, 2026
Omnicell beats Q3 revenue estimates by 5%, stock surges 64% since earnings report

Omnicell, a provider of medication management automation and adherence tools for healthcare systems and pharmacies, reported third-quarter revenues of $310.6 million, up 10% year on year and exceeding analysts' expectations by 5%. The company also beat earnings per share estimates. "We are pleased with the strong financial performance delivered in the third quarter," said Randall Lipps, Omnicell's chairman, president and chief executive officer. The stock has risen 64% since reporting results and currently trades at $48.49. The healthcare technology for providers sector faces mixed conditions, with opportunities from AI-driven tools and government digitisation incentives offset by challenges including long sales cycles, slow adoption rates, and tightening hospital budgets. The four companies tracked in this sector reported satisfactory third-quarter results overall, though share prices have declined 5.3% on average since earnings.

Specialty Pharmacy Continuum
Aug 18th, 2025
Texas Children's Hospital Adopts RFID for OR Med Management

This May, medication and supply management technology company Omnicell launched a new radio frequency identification (RFID)-enabled device to manage medications in the operating room.

StreetInsider
Mar 24th, 2025
Omnicell (OMCL) appoints Perry Genova as CTO

Omnicell, Inc. (Nasdaq: OMCL), a leader in transforming the pharmacy and nursing care delivery model, today announced that Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, effective March 31, 2025.